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observation of possible symptoms of opioid overdose. Vague signs 
such as extreme sleepiness, breathing problems, or even “pinpoint” 
pupils may prompt a family member or close friend to whip out this 
life-saving device and spring into action!
http://evzio.com/hcp/index.php
For Evzio to be effective, it will have to be prescribed and probably 
paid for by either the patient or the prescription insurance company. 
Will the prescriber be willing to address the risk of opioid overdose 
to their patients on high-dose opioids or just those with known 
substance abuse or those with a history of addiction or past stays in 
detox programs? Are we really naïve enough to believe that only those 
people that are prescribed these powerful medications are at risk? 
The numbers of “users” who acquire these pain killers from friends, 
relatives and illegal “dealers” is unknown but surely an enormous and 
unacceptable number that clearly has overwhelmed the ability of law 
enforcement to eliminate.
I am all for prescribers suggesting Evzio to all their chronic 
pain patients on high-dose opioids. The need for an explanation 
on the risk of respiratory depression and death is crucial even if the 
prescriber does not suspect abuse of opioids. Unintentional overdose 
is a common term used by physicians and medical examiners after 
patients consumed dozens of medications, often at extremely high 
doses-many not even prescribed or acquired legally. Sounds a lot 
like suicide? Unfortunately these are reported as “accidental” and 
continue to be counted the same as a car accident of falling off a 
building. For these and many other and unclear reasons most autopsy 
reports will not even suggest that a patient was attempting to take 
their life-without a suicide note! 
This brings us back to the question of will this medication actually 
be used by a family member if they see someone on their couch 
breathing shallow?
It is unbelievable how much positivity is being reported with 
naloxone! Reports of it being without risk or side effects have suggested 
that the medication can be used by Good Samaritans who happen 
to be bystanders positioned around the country with open arms and 
Physicians employed in operating and emergency rooms have 
utilized opioid antagonist for almost half a century for the treatment 
of opioid overdose. The prototype antagonist remains naloxone 
hydrochloride, which actually received FDA approval back in 1971. 
Why after so many years on the market is this medication now 
being formulated in the form of an easy to use “auto-injector” that 
was designed for non-medical professionals to be able to utilize at a 
moment’s notice? Could this wonder product, being hailed as the best 
possible safety tool available for life threatening opioid emergencies 
actual make heroes out of lay people? [1].
Will marketing and providing to the family and caregivers of 
chronic pain patients prevent the epidemic of opioid medication 
related deaths of people in our country? What else can be done by 
physicians and the U.S. Food and Drug Administration (FDA) 
to reduce the unbelievable statistic of a death every 36 minutes 
from an opioid overdose in the United States? With upwards of 
17,000 Americans dying yearly from prescription opioid overdose, 
accidently or intentionally via suicide& deliberate misuse, and 
constantly consuming more and more of these powerful painkillers-
the million dollar question remaining to be answered is:  will a new 
drug formulation device in the hands of laypeople really make a dent 
in this crisis that in recent years has actually surpassed car accidents 
as the leading cause of accidental death? [2].
This new formulation Evzio contains naloxone in a new useful 
device: an “auto-injector” that was recently approved for the 
emergency treatment of suspected opioid overdose. The FDA and 
physicians see Evzio as a new “tool” to combat opioid abuse/misuse 
related deaths. It will work in a manner similar to the epinephrine pen 
which is marketed for the acute treatment of anaphylaxis. (EVZIO 
contains a speaker that provides voice instructions to guide the user 
through each step of the injection).When activated, an automatically 
inserted needle delivers 0.4 mg of naloxone hydrochloride injection 
intramuscularly or subcutaneously and afterwards fully retracts the 
needle into its housing [3].
Caregivers will be expected to utilize this medication after an 
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equipped with the life-saving antidote and unwavering willingness to 
assist doctors and reduce society concerns of opioid death. Caregivers 
must be educated about what to expect AFTER giving naloxone... 
sweating, goose-bumps, increased heart rate, agitation, withdrawal 
symptoms, and the lack of efficacy for overdoses of other medications 
that may be onboard including benzodiazepines, etc. 
It is also very important to remain aware that most opioids will 
last longer than naloxone-so good luck encouraging patients to head 
on down to the emergency room for additional doses of naloxone, 
and further care including management of withdrawal symptoms.
Any physician, paramedic or researcher with experience injecting 
naloxone into an unconscious patient, unresponsive due to large doses 
of opioids on board, is well aware of dramatic increases in both blood 
pressure (BP) and heart rate (HR) upon its pharmacological response. 
It is not surprising that rapid “withdrawal-like” symptomatology 
after IM or IV opioid antagonist treatment, including an unpleasant 
increase in severe anxiety, palpitations, and hypertensive changes 
will make this “marketed” and “inferred” safe and easy treatment a 
very difficult and even potentially dangerous situation for these non-
medical professional bystanders who are only trying to help revive 
someone who may be unresponsive in their humble and untrained 
opinion.
Safety and complications from treatment apparently are not being 
advertised as an issue with this newly marketed naloxone- injector 
according to evzio.com:
“No clinically significant safety findings”
“No serious adverse events”
“No volunteer discontinuation or withdrawal”
This is not really that surprising since “real- world- use” implies“ 
out of a hospital settings” with obvious reduced availability of 
heart rate or blood pressure monitoring devices or even medical 
professionals that could use them properly and death that occurred 
despite utilization of the naloxone-injector could be easily determined 
to be due to “late” administration of this anecdote. 
With drug companies downplaying any cardiovascular 
complications or even side effects being associated with naloxone, 
it will be interesting to watch for sympathomimetic-catecholinergic 
surge with a corresponding rapid pulse following naloxone 
administration. Myocardial Infarction/Stroke complications can and 
will occur-especially in patients with risk factors including smoking 
history, obesity, sedentary lifestyle (from their chronic pain) or 
hypertension, hyperlipidemia and tachycardia.
The development of a severe hypertensive response after the 
administration of the opiate antagonist naloxone was evaluated 
in one study that characterized the potentially dangerous role of 
blocking or antagonizing opioids and the potential alteration in 
the regulation of blood pressure in patients. One individual studied 
showed significant mean arterial pressure changes with a rise from a 
baseline of 107 mmHg to 147 mmHg 145 min after naloxone injection 
and infusion. After stopping naloxone, his blood pressure rapidly 
returned to baseline. Thus, endogenous opioids appear to regulate 
blood pressure in some hypertensive patients and opiate antagonists 
must be administered with caution to these individuals [4].
It is shocking that despite evidence of cardiovascular side effects 
in studies, few warnings have been provided about untoward side 
effects that could manifest as dramatic changes in vital signs following 
administration by lay people.
This is not the first time that naloxone has been suggested as a 
panacea. Since naloxone is needed as rapidly as possible in an operating 
room situation-intravenously use to reverse opioid overdose is the 
most preferred route. Over the years, countless researchers have 
tinkered with oral formulations for both treatment and reduction of 
associated opioid agonist complications. A slowed gastrointestinal- 
related complication has plagued man since the first use of opioid 
agonists, and continues to contribute to both the unpleasantness and 
even immobility of chronic pain patients. It is not uncommon for 
patients on large doses of chronic and powerful opioids to require 
multiple daily doses of stimulant cathartics and stool-softeners in an 
effort to have regular bowel functions. The ineffectiveness of laxatives 
to target the underlying cause of opioid-induced inhibition of gastric 
motility and the resulting chronic associated constipation have led to 
the development of treatments that utilize opioid receptor antagonists 
including naloxone and methylnaltrexone to target receptors in the 
gut preferentially.
Methylnaltrexone marketed under the name Relistor provides 
peripherally-acting-opioid antagonism that has the ability to reverse 
constipation in patients using opioid-agonists without affecting 
analgesia or even precipitating withdrawals. A permanently charged 
tetravalent nitrogen atom in its design prevents the crossing of the 
blood–brain barrier. This predominant antagonist effects counteracts 
troubling opioid-induced side effects such as itching and constipation, 
all while not minimizing opioid effects in the brain responsible for 
analgesia.
RELISTOR is marketed as a prescription medication indicated for 
the treatment of opioid-induced constipation (OIC) in patients with 
advanced illness who are receiving palliative care, when response to 
laxative therapy has not been sufficient. Use of RELISTOR beyond 
four months has not been studied. The usual dose schedule for 
RELISTOR is once every other day, as needed, but no more than once 
in a 24-hour period [5].
It has been suggested that naloxone, when given orally, has 
negligible bioavailability but may actually counteract opioid-induced 
constipation by blocking the action of opioid medications locally in 
the gut. Because of a sophisticated understanding of pharmacokinetic 
properties, naloxone activity in the gastrointestinal tract presumably 
occurs before almost complete metabolism by the liver to the 
medications necessary reduction to negligible drug activity in the 
Central Nervous System (CNS) where opioid (pain) receptors 
are located. Central effects of the oral naloxone are minimized by 
utilizing sparse doses that benefit colon transit time and minimize 
complications that would impair analgesia. 
Utilizing this research, a new modified-release combination 
product containing the strong opioid oxycodone plus the opioid 
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antagonist naloxone is being researched for the treatment of “severe 
pain, which can be adequately managed only with opioid analgesics”. 
It is believed that this combination has unique characteristics that 
“naloxone is added to counteract opioid-induced constipation by 
blocking the action of oxycodone at opioid receptors locally in the 
gut”. If research proves claims of “superior GI [gastrointestinal] 
tolerability compared to previous treatment in a clinical practice 
study” to be accurate, it will be just a matter of time before more 
and diverse opioids will be reformulated with a combined agonist/
antagonist formula [4].
The marketing of oxycodone/naloxone tablets, and other 
fixed dose combination products including previously marketed 
pentazocine-naloxone and morphine/ naltrexone utilized agonist/
antagonist has been attempted in an effort to prevent reactions 
from crushing or injecting these combination products. Naloxone 
was considered a wonderful deterrent to tampering with oral pain 
medications in an effort to prevent a patient from crushing and 
injecting an oral opioid with the hope of getting a “greater high or 
euphoria rush”.
The providing of warnings by physicians and pharmacists were 
thought to reduce the incidence of severe and potentially lethal misuse-
reactions. Unfortunately, the morphine/naltrexone formulation was 
withdrawn not due to any failure by the science of the formulation 
including any insignificant amount of sequestered naltrexone 
reaching systemic circulation, but because of reports of potentially 
fatal reaction upon patient tampering and the subsequent release 
of naltrexone blunting the euphoria of opioids and precipitating 
dangerous opioid withdrawal sequelae in opioid-dependent patient. 
Suboxone (buprenorphine and naloxone) has become a very popular 
treatment for opiate addiction and while abuse is still possible, it 
appears to have less euphoria and reduced analgesia effects compared 
with full-opioid agonists.
Naltrexone basically has the same pharmacological effects as 
naloxone, but it is longer acting and does possess potent pharmacologic 
effects when used orally. Naltrexone is often utilized prophylactically 
to maintain abstinence from opioids and administered by specially 
trained medical supervision under anesthesia to provide rapid 
detoxification in addicted patients wishing to bypass the unpleasant 
withdrawal syndrome. Naltrexone for Opiate Dependence has not 
proven to be a breakthrough in allowing patients to remain free of 
opioids. Patients cannot be started on this preventative treatment 
until they have already been opioid free for at least a week due to its 
ability to precipitate an opioid withdrawal in opioid-tolerant patient.
VIVITROL® (naltrexone for extended-release injectable 
suspension) is a long-acting opioid antagonist that was approved 
by the FDA in 2006. It has been used as a treatment for alcohol 
dependence and to prevent relapse to opioid dependence after opioid 
detoxification. The recommended dose is 380 mg intramuscularly 
once a month.
Due to its powerful antagonistic properties, its use does have 
potential dangerous consequences with its use. The blocking of 
exogenous opioid effects could result in the necessity to utilize 
potentially life-threatening opioid doses to sufficiently overcome the 
competitive receptor blockade due to its unique pharmacological 
properties:  it is injected into a muscle, and cannot be removed from 
the body, it duration (lasts for one month).  Since the medication 
blocks the effects of opioid-containing medicines that might 
otherwise be prescribed for a patient for pain, cough, or diarrhea, a 
patient may be limited in their ability to receive any opioid agonist 
benefits if needed in the case of an emergency or severe illness.
In addition, hepatotoxicity is a known consequence with oral 
or injectable naltrexone use. If symptoms or lab values indicate any 
potential liver damage or hepatitis including stomach area pain lasting 
more than a few days, yellowing of the whites of eyes, dark urine or 
even tiredness would necessitate a medical judgment to discontinue 
treatment would seem prudent.
Stopping overdoses is obviously not enough to combat the 
current enormous multifactorial problem of opioid misuse and 
abuse. Recent government pressures have also been focused on 
rescheduling hydrocodone-based products in an effort to reduce the 
quantities available for illegal or even legally prescribed use to the 
more restrictive Drug Enforcement Administration (DEA) schedule/
class “II”. Currently refills and telephoned prescriptions are available 
for the less restrictive class III-V opioid-based medications, with the 
proposed rescheduling to class-II, refills and telephoned prescriptions 
will no longer be allowed under the law. This of course does not reduce 
the amount of opioids prescribed, abused or diverted-it just makes 
prescribers of class-II more cognizant of its restrictive nature and 
requires more work for writer (physician), dispenser (pharmacist/
nurse), and patient (potential chronic pain patient or possible abuser 
of medications). 
Pharmacist and Physicians for the most part do not support these 
rescheduling measures due to the proposed increase in record keeping 
requirements and additional roadblocks to filling what has been 
considered useful and first-line for the treatment of mild, moderate 
and moderately severe pain. With a potential switch from its long-
time position as a class III controlled substance to the class II location, 
concerns about what forces-if any will prevent physicians from leap-
frogging their patients to the more powerful morphine, methadone, 
hydromorphone, oxymorphone, or even oxycodone products?
Another potential solution includes pharmacy manufactures 
and researchers designing and creating more abuse-deterrent opioid 
formulations as another strategy suggested by the medical community 
and government theorist. Risk Evaluation and Mitigation Strategies 
(REMS) which include FDA Mandated med-guides together with 
Prescription Drug Monitoring Programs (PDMP) have done very 
little possibly due to little cohesiveness between prescribers and 
pharmacists to address this problem and work toward the creation of 
a successful strategy to combat abuse and misuse. 
Nature gave man opioid agonists and scientists have created 
antagonists to combat them. Which will prove the most powerful in 
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the end? These antagonists sure are providing an interesting subplot 
to the battle against opioid agonists. Sometimes in medicine it is 
hard to determine what characteristics describe the antagonist hero 
(naloxone) and that of the protagonist villain (Opioids)?  Is the hero 
(naloxone) really going to protect humanity from a powerful enemy 
(Opioids)? Is pain no longer the evil bad guy? Are the prescribers, 
pharmacists and drug pushers the enemies now? Are patients really 
just non-competitors in this scenario and unable to stay out of “harm’s 
way” or utilize powerful pain management treatments safely due to 
unmanageable side effects or life-threatening dangers? We will see!  
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